Global Antihelminthics Market Overview
The global antihelminthics market size was estimated to be worth USD 1.5 billion in 2022, and it will grow from USD 1.6 billion in 2023 to USD 3.2 billion by 2032, with a compound annual growth rate (CAGR) of 8.92% throughout the course of the forecast period (2023 - 2032).
Antihelminthics are a group of antiparasitic drugs that are prescribed to kill parasites (helminthes) in common parasitic infestations such as fasciolasis, filariasis, angiostrongylosis, and others.
Diseases such as schistosomiasis, ascariasis, whipworm infection, and other intestinal infections have become prevalent globally which induces high demand for antihelminthics drugs. As per the reports of the World Health Organization (WHO), over 1.5 Billion people were found to be infected with soil-transmitted helminthes on a global scale. Also, a recent report by WHO suggests that more than 880 million children require treatment for parasitic diseases.
Parasitic diseases such as schistosomiasis, whipworm infection, ascariasis, and other intestinal infections are most prevalent in East Asia, sub-Saharan Africa, and India. Parasitic diseases occur in unhygienic conditions in the developing countries where a majority of the population suffering from such diseases induce high demand for antihelminthics and boost the growth of the global antihelminthics market.
In the last few years, extensive research programs have been initiated which has resulted in the development and modification of existing drugs. The pharmaceutical industry has been able to produce a wide spectrum of highly effective antihelminthics which has been a plus for the growth of the global antihelminthics market.
Other factors spurring the growth of the global anthelminthic market include growing geriatric population and rapidly expanding healthcare sector, especially in developing economies.
On the other hand, the growth of the global antihelminthics market might be impeded by the side effects associated with antihelminthics. Also, overuse of antihelminthics leads to the emergence of resistant microbes which might affect the efficacy of antihelminthics.
Segmentation
The global antihelminthics market has been segmented based on type, application, and end user.
By type, the global antihelminthics market has been segmented into benzimidazoles, abamectin, salicylanilides, praziquantel, and others.
The Benzimidazoles segment has been further segmented into benzimidazoles, albendazole, mebendazole, thiabendazole, and others. The benzimidazoles segment accounts for the largest share of the market owing to their long history and efficiency. Additionally, they are easily availed in the market which drives the segment growth further.
The Salicylanilides segment has been further segmented into niclosamide, oxyclozanide, rafoxanide, and others.
By application, the global antihelminthics market has been segmented into schistosomiasis, fasciolasis, filariasis, angiostrongylosis, ascariasis, giardiasis, and others.
By end user, the global antihelminthics market has been segmented into hospitals, clinics, and others.
Regional Analysis
By region, the global antihelminthics market has been segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas dominate the global antihelminthics market. High prevalence of parasitic diseases and presence of a vast base of geriatric population boosts the growth of the antihelminthics market in the Americas. Government support in the form of R&D funds, huge number of patients suffering from autoimmune diseases and developed pharmaceutical industry too augur the growth of the market.
Europe follows the Americas closely and accounts for the second largest share of the market. Extensive R&D efforts and increasing geriatric population drive the market in Europe.
APAC is likely to be the fastest growing market for antihelminthics. The developing economies in the region present a myriad of opportunities for the growth of the antihelminthics market. Surging prevalence of parasitic and digestive disorders in the region, rapid economic growth and expanding healthcare sector stimulates the growth of the antihelminthics market in APAC.
The MEA market accounts for the least share of the market owing to limited availability of medical facilities and poor economic conditions in Africa. The majority share of the MEA market is held by the Middle East since it has a well-developed healthcare sector and spends considerably on healthcare facilities.
Competitive Landscape
The top key antihelminthics market players include Sanofi (US), Merck & Co., Inc. (US), GlaxoSmithKline Plc. (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), ALLERGAN (Ireland), Mentis Pharma Ltd. (India), Abbott (US), ZEISS International (Germany), Astellas Pharma Inc. (Japan), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), and Pfizer Inc. (US).
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
